Steven A. Lietman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven A. Lietman has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Michael A. Levine
Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia , Philadelphia, PA 19104
14 shared publications Changlin Ding
Biomedical Engineering (S.A.L., C.D., M.A.L.), Cleveland Clinic Lerner Research Institute and Foundation, Cleveland, Ohio 44195
4 shared publications- Bjorn Reino Olsen
Department of Developmental Biology, Harvard School of Dental Medicine, Harvard University, Boston, MA 02115, USA
2 shared publications Brian P. Rubin
Department of Anatomic Pathology, Cleveland Clinic Foundation
2 shared publications- Chun Fan
Department of Biomedical Engineering, The Cleveland Clinic, Cleveland, OH 44195, USA
2 shared publications - Ernst J. Reichenberger
Department of Reconstructive Sciences, Center for Regenerative Medicine and Skeletal Development, University of Connecticut Health Center, Farmington, CT, USA
2 shared publications
Latest Publications
- 1 February 2017
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 62, 67-77
Articular cartilage repair: Current needs, methods and research directions
- 1 February 2017
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 62, 67-77
Articular cartilage repair: Current needs, methods and research directions
- Open Access
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Orthopedics
- Vol. 7 (3) , 149-55
Induced pluripotent stem cells in cartilage repair
Articular cartilage repair techniques are challenging. Human embryonic stem cells and induced pluripotent stem cells (iPSCs) theoretically provide an unlimited number of specialized cells which could be used in articular cartilage repair. However thus far chondrocytes from iPSCs have been created primarily by viral transfection and with the use of cocultured feeder cells. In addition chondrocytes derived from iPSCs have usually been formed in condensed cell bodies (resembling embryoid bodies) that then require dissolution with consequent substantial loss of cell viability and phenotype. All of these current techniques used to derive chondrocytes from iPSCs are problematic but solutions to these problems are on the horizon. These solutions will make iPSCs a viable alternative for articular cartilage repair in the near future.
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Orthopedics
- Vol. 7 (3) , 149-55
Open AccessInduced pluripotent stem cells in cartilage repair
Articular cartilage repair techniques are challenging. Human embryonic stem cells and induced pluripotent stem cells (iPSCs) theoretically provide an unlimited number of specialized cells which could be used in articular cartilage repair. However thus far chondrocytes from iPSCs have been created primarily by viral transfection and with the use of cocultured feeder cells. In addition chondrocytes derived from iPSCs have usually been formed in condensed cell bodies (resembling embryoid bodies) that then require dissolution with consequent substantial loss of cell viability and phenotype. All of these current techniques used to derive chondrocytes from iPSCs are problematic but solutions to these problems are on the horizon. These solutions will make iPSCs a viable alternative for articular cartilage repair in the near future.
- Open Access
- 21 June 2013
- Published by Sciedu Press in Journal of Solid Tumors
- Vol. 3 (4) , p44
A single institution analysis of recurrence in myxoid liposarcoma
Background: Myxoid liposarcomas account for approximately one third of all liposarcomas and typically present as a slow-growing, deep-seated tumor in the lower extremity. Although approximately one-third of patients develop metastases and eventually die from their tumors, prognostic factors for recurrence have not been thoroughly studied. The effects of radiotherapy and perioperative allogeneic blood transfusions on tumor recurrence in primary myxoid liposarcomas were investigated. Patients and Methods: A retrospective review of 47 primary myxoid liposarcomas treated at a single institution was completed. Morphologic diagnoses were confirmed by soft tissue pathologists without prior knowledge of the clinical features, treatment, or outcome. Associations among treatment factors and recurrence were examined. Results: Four (9%) and fourteen (30%) patients developed local recurrences and distant metastases, respectively. The median follow-up time was 54 months. There were no local recurrences among those who received radiotherapy, thus producing a significant decrease in local recurrence in those patients who received radiotherapy (p[Cox model]=0.010). The receipt of ≥3 blood transfusions correlated with an increase in tumor local recurrence (p[Cox model]=0.030). Conclusions: Radiotherapy and perioperative blood transfusion quantity may have an effect on tumor recurrence and warrant further investigation. Mini-Abstract: Radiotherapy and perioperative blood transfusion quantity have a significant effect on myxoid liposarcoma recurrence.
- 21 June 2013
- Published by Sciedu Press in Journal of Solid Tumors
- Vol. 3 (4) , p44
Open AccessA single institution analysis of recurrence in myxoid liposarcoma
Background: Myxoid liposarcomas account for approximately one third of all liposarcomas and typically present as a slow-growing, deep-seated tumor in the lower extremity. Although approximately one-third of patients develop metastases and eventually die from their tumors, prognostic factors for recurrence have not been thoroughly studied. The effects of radiotherapy and perioperative allogeneic blood transfusions on tumor recurrence in primary myxoid liposarcomas were investigated. Patients and Methods: A retrospective review of 47 primary myxoid liposarcomas treated at a single institution was completed. Morphologic diagnoses were confirmed by soft tissue pathologists without prior knowledge of the clinical features, treatment, or outcome. Associations among treatment factors and recurrence were examined. Results: Four (9%) and fourteen (30%) patients developed local recurrences and distant metastases, respectively. The median follow-up time was 54 months. There were no local recurrences among those who received radiotherapy, thus producing a significant decrease in local recurrence in those patients who received radiotherapy (p[Cox model]=0.010). The receipt of ≥3 blood transfusions correlated with an increase in tumor local recurrence (p[Cox model]=0.030). Conclusions: Radiotherapy and perioperative blood transfusion quantity may have an effect on tumor recurrence and warrant further investigation. Mini-Abstract: Radiotherapy and perioperative blood transfusion quantity have a significant effect on myxoid liposarcoma recurrence.
- 1 June 2013
- Vol. 10 (Suppl 2) , 389-96
Fibrous dysplasia.
Fibrous dysplasia is a developmental abnormality of bone that is characterized by a highly disorganized mixture of immature fibrous tissue and fragments of immature trabecular bone. Fibrous dysplasia may arise as a single, discrete (monostotic) lesion or can occur with a more widespread distribution with multiple lesions that affect many bones (oligo- or polyostotic). Fibrous dysplasia is usually an isolated skeletal finding but can sometimes occur as a component of a multisystem developmental disorder known as McCune-Albright syndrome (MAS) that is also associated with endocrine hyperfunction (e.g. precocious puberty) and caf au lait cutaneous macules. The identification of activating mutations in GNAS in a subset of human GH-secreting pituitary tumors and autonomously functioning human thyroid tumors provided the initial basis for understanding the molecular pathophysiology of McCune-Albright syndrome and fibrous dysplasia. These observations led to the concept that activating mutations of the GNAS gene convert it into a putative oncogene referred to as gsp (Gsa or Gas). The classic radiographic feature of fibrous dysplasia is a hazy, radiolucent, or ground-glass, pattern resulting from the defective mineralization of immature dysplastic bone; it is usually strikingly different from the radiographic appearance of normal bone, calcified cartilage, or soft tissue. The surgical approach to fibrous dysplasia should in general be conservative. Recent research suggests that the WntlB-catenin pathway may play a role in fibrous dysplasia as patients with activating GNAS mutations specifically showed that Gas mutations activated Wnt/B-catenin signaling. Thus inhibition of 8-catenin signaling or silencing GNAS alleles that encode constitutively active Gsa molecules in fibrous dysplasia and McCune-Albright syndrome offer potential therapeutic promise and deserve further study. In summary fibrous dysplasia is a developmental abnormality of bone with a known molecular etiology; Further knowledge about the molecular pathology of fibrous dysplasia may lead to improved conservative therapies in the near future.
- 1 June 2013
- Vol. 10 (Suppl 2) , 389-96
Fibrous dysplasia.
Fibrous dysplasia is a developmental abnormality of bone that is characterized by a highly disorganized mixture of immature fibrous tissue and fragments of immature trabecular bone. Fibrous dysplasia may arise as a single, discrete (monostotic) lesion or can occur with a more widespread distribution with multiple lesions that affect many bones (oligo- or polyostotic). Fibrous dysplasia is usually an isolated skeletal finding but can sometimes occur as a component of a multisystem developmental disorder known as McCune-Albright syndrome (MAS) that is also associated with endocrine hyperfunction (e.g. precocious puberty) and caf au lait cutaneous macules. The identification of activating mutations in GNAS in a subset of human GH-secreting pituitary tumors and autonomously functioning human thyroid tumors provided the initial basis for understanding the molecular pathophysiology of McCune-Albright syndrome and fibrous dysplasia. These observations led to the concept that activating mutations of the GNAS gene convert it into a putative oncogene referred to as gsp (Gsa or Gas). The classic radiographic feature of fibrous dysplasia is a hazy, radiolucent, or ground-glass, pattern resulting from the defective mineralization of immature dysplastic bone; it is usually strikingly different from the radiographic appearance of normal bone, calcified cartilage, or soft tissue. The surgical approach to fibrous dysplasia should in general be conservative. Recent research suggests that the WntlB-catenin pathway may play a role in fibrous dysplasia as patients with activating GNAS mutations specifically showed that Gas mutations activated Wnt/B-catenin signaling. Thus inhibition of 8-catenin signaling or silencing GNAS alleles that encode constitutively active Gsa molecules in fibrous dysplasia and McCune-Albright syndrome offer potential therapeutic promise and deserve further study. In summary fibrous dysplasia is a developmental abnormality of bone with a known molecular etiology; Further knowledge about the molecular pathology of fibrous dysplasia may lead to improved conservative therapies in the near future.
- 1 August 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 425 (1) , 25-32
Cloning and characterization of the human SH3BP2 promoter
- 1 August 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 425 (1) , 25-32
Cloning and characterization of the human SH3BP2 promoter
- Open Access
- 24 May 2012
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 7 (S1) , S6
Cherubism: best clinical practice
Cherubism is a skeletal dysplasia characterized by bilateral and symmetric fibro-osseous lesions limited to the mandible and maxilla. In most patients, cherubism is due to dominant mutations in theSH3BP2gene on chromosome 4p16.3. Affected children appear normal at birth. Swelling of the jaws usually appears between 2 and 7 years of age, after which, lesions proliferate and increase in size until puberty. The lesions subsequently begin to regress, fill with bone and remodel until age 30, when they are frequently not detectable.Fibro-osseous lesions, including those in cherubism have been classified as quiescent, non-aggressive and aggressive on the basis of clinical behavior and radiographic findings. Quiescent cherubic lesions are usually seen in older patients and do not demonstrate progressive growth. Non-aggressive lesions are most frequently present in teenagers. Lesions in the aggressive form of cherubism occur in young children and are large, rapidly growing and may cause tooth displacement, root resorption, thinning and perforation of cortical bone.Because cherubism is usually self-limiting, operative treatment may not be necessary. Longitudinal observation and follow-up is the initial management in most cases. Surgical intervention with curettage, contouring or resection may be indicated for functional or aesthetic reasons. Surgical procedures are usually performed when the disease becomes quiescent. Aggressive lesions that cause severe functional problems such as airway obstruction justify early surgical intervention.
- 24 May 2012
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 7 (S1) , S6
Open AccessCherubism: best clinical practice
Cherubism is a skeletal dysplasia characterized by bilateral and symmetric fibro-osseous lesions limited to the mandible and maxilla. In most patients, cherubism is due to dominant mutations in theSH3BP2gene on chromosome 4p16.3. Affected children appear normal at birth. Swelling of the jaws usually appears between 2 and 7 years of age, after which, lesions proliferate and increase in size until puberty. The lesions subsequently begin to regress, fill with bone and remodel until age 30, when they are frequently not detectable.Fibro-osseous lesions, including those in cherubism have been classified as quiescent, non-aggressive and aggressive on the basis of clinical behavior and radiographic findings. Quiescent cherubic lesions are usually seen in older patients and do not demonstrate progressive growth. Non-aggressive lesions are most frequently present in teenagers. Lesions in the aggressive form of cherubism occur in young children and are large, rapidly growing and may cause tooth displacement, root resorption, thinning and perforation of cortical bone.Because cherubism is usually self-limiting, operative treatment may not be necessary. Longitudinal observation and follow-up is the initial management in most cases. Surgical intervention with curettage, contouring or resection may be indicated for functional or aesthetic reasons. Surgical procedures are usually performed when the disease becomes quiescent. Aggressive lesions that cause severe functional problems such as airway obstruction justify early surgical intervention.
- Open Access
- 1 January 2012
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 7 (Suppl 1) , S5
The role of SH3BP2 in the pathophysiology of cherubism
Cherubism is a rare bone dysplasia that is characterized by symmetrical bone resorption limited to the jaws. Bone lesions are filled with soft fibrous giant cell-rich tissue that can expand and cause severe facial deformity. The disorder typically begins in children at ages of 2-5 years and the bone resorption and facial swelling continues until puberty; in most cases the lesions regress spontaneously thereafter. Most patients with cherubism have germline mutations in the gene encoding SH3BP2, an adapter protein involved in adaptive and innate immune response signaling. A mouse model carrying a Pro416Arg mutation in SH3BP2 develops osteopenia and expansile lytic lesions in bone and some soft tissue organs. In this review we discuss the genetics of cherubism, the biological functions of SH3BP2 and the analysis of the mouse model. The data suggest that the underlying cause for cherubism is a systemic autoinflammatory response to physiologic challenges despite the localized appearance of bone resorption and fibrous expansion to the jaws in humans.
- 1 January 2012
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 7 (Suppl 1) , S5
Open AccessThe role of SH3BP2 in the pathophysiology of cherubism
Cherubism is a rare bone dysplasia that is characterized by symmetrical bone resorption limited to the jaws. Bone lesions are filled with soft fibrous giant cell-rich tissue that can expand and cause severe facial deformity. The disorder typically begins in children at ages of 2-5 years and the bone resorption and facial swelling continues until puberty; in most cases the lesions regress spontaneously thereafter. Most patients with cherubism have germline mutations in the gene encoding SH3BP2, an adapter protein involved in adaptive and innate immune response signaling. A mouse model carrying a Pro416Arg mutation in SH3BP2 develops osteopenia and expansile lytic lesions in bone and some soft tissue organs. In this review we discuss the genetics of cherubism, the biological functions of SH3BP2 and the analysis of the mouse model. The data suggest that the underlying cause for cherubism is a systemic autoinflammatory response to physiologic challenges despite the localized appearance of bone resorption and fibrous expansion to the jaws in humans.
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17, 28-32
Preimplantation Genetic Diagnosis for Hereditary Endocrine Disease
- 1 July 2011
- Published by Elsevier in Endocrine Practice
- Vol. 17, 28-32
Preimplantation Genetic Diagnosis for Hereditary Endocrine Disease
- Open Access
- 29 March 2011
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 29 (10) , 1521-1527
Decreased SH3BP2 inhibits osteoclast differentiation and function
Germline mutations in SH3BP2 gene have been identified in patients with cherubism, a skeletal disorder characterized by excessive osteoclastic bone resorption that is limited to the mandible and maxilla. We previously demonstrated that SH3BP2 overexpression in Raw264.7 cells increased RANKL‐induced osteoclastogenesis. Here, we examine the effect of decreased SH3BP2 on osteoclastogenesis. shRNA knockdown of SH3BP2 decreased PLCγ2 phosphorylation and NFATc1 expression, and reduced the expression of osteoclast‐specific genes. In BMMs knockdown of SH3BP2 led to reductions in both the number and the surface area of TRAP positive and multinucleated osteoclasts. Bone resorptive activity was also dramatically blocked by shRNA knockdown of SH3BP2. Similarly Sh3bp2(−/−) deficient mice BMMs formed smaller osteoclasts that stained less with TRAP than wild‐type mice. Taken together, this study demonstrates that SH3BP2 knockdown significantly decreases osteoclast differentiation and function. These results suggest that SH3BP2 plays a critical role in osteoclastogenesis and is a potential target for suppression of pathologic bone resorption. © 2011 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 29: 1521–1527, 2011
- 29 March 2011
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 29 (10) , 1521-1527
Open AccessDecreased SH3BP2 inhibits osteoclast differentiation and function
Germline mutations in SH3BP2 gene have been identified in patients with cherubism, a skeletal disorder characterized by excessive osteoclastic bone resorption that is limited to the mandible and maxilla. We previously demonstrated that SH3BP2 overexpression in Raw264.7 cells increased RANKL‐induced osteoclastogenesis. Here, we examine the effect of decreased SH3BP2 on osteoclastogenesis. shRNA knockdown of SH3BP2 decreased PLCγ2 phosphorylation and NFATc1 expression, and reduced the expression of osteoclast‐specific genes. In BMMs knockdown of SH3BP2 led to reductions in both the number and the surface area of TRAP positive and multinucleated osteoclasts. Bone resorptive activity was also dramatically blocked by shRNA knockdown of SH3BP2. Similarly Sh3bp2(−/−) deficient mice BMMs formed smaller osteoclasts that stained less with TRAP than wild‐type mice. Taken together, this study demonstrates that SH3BP2 knockdown significantly decreases osteoclast differentiation and function. These results suggest that SH3BP2 plays a critical role in osteoclastogenesis and is a potential target for suppression of pathologic bone resorption. © 2011 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 29: 1521–1527, 2011
- 16 December 2010
- Published by Wiley in Journal of Surgical Oncology
- Vol. 103 (1) , 85-91
Prognosticators in thigh soft tissue sarcomas
Background: In sarcoma patients the roles of smoking history, family cancer history, and leukoreduced blood transfusions have not been studied and the effect of preoperative radiation on blood loss has not been examined.Methods: Seventy‐seven patients with non‐metastatic and non‐recurrent thigh sarcomas surgically treated at the Cleveland Clinic were identified. Among patient variables studied were: close family history of cancer, perioperative transfusion history, smoking history, and radiation history. Median follow‐up for the survivors was 3.2 years.Results: We found that tumor grade, transfusion >3 U (P = 0.022), and pre‐ or post‐operative radiation therapy (P = 0.041) were risk factors for distant metastasis. Tumor grade (P = 0.008), positive smoking history (P = 0.039), and >3 U of non‐leukoreduced blood transfused (P = 0.037) were risk factors for death of any‐cause. Close family history of cancer correlated with having a grade 3 sarcoma (P = 0.044). Neoadjuvant radiotherapy correlated with >3 U of blood transfused (P = 0.001) and biopsy performed at the treating institution led to a significant decrease in rate of recurrence (P = 0.016).Conclusions: We present novel findings in terms of transfusions, family history of cancer and site of initial biopsy in sarcoma patients. J. Surg. Oncol. 2011;103:85–91.
- 16 December 2010
- Published by Wiley in Journal of Surgical Oncology
- Vol. 103 (1) , 85-91
Prognosticators in thigh soft tissue sarcomas
Background: In sarcoma patients the roles of smoking history, family cancer history, and leukoreduced blood transfusions have not been studied and the effect of preoperative radiation on blood loss has not been examined.Methods: Seventy‐seven patients with non‐metastatic and non‐recurrent thigh sarcomas surgically treated at the Cleveland Clinic were identified. Among patient variables studied were: close family history of cancer, perioperative transfusion history, smoking history, and radiation history. Median follow‐up for the survivors was 3.2 years.Results: We found that tumor grade, transfusion >3 U (P = 0.022), and pre‐ or post‐operative radiation therapy (P = 0.041) were risk factors for distant metastasis. Tumor grade (P = 0.008), positive smoking history (P = 0.039), and >3 U of non‐leukoreduced blood transfused (P = 0.037) were risk factors for death of any‐cause. Close family history of cancer correlated with having a grade 3 sarcoma (P = 0.044). Neoadjuvant radiotherapy correlated with >3 U of blood transfused (P = 0.001) and biopsy performed at the treating institution led to a significant decrease in rate of recurrence (P = 0.016).Conclusions: We present novel findings in terms of transfusions, family history of cancer and site of initial biopsy in sarcoma patients. J. Surg. Oncol. 2011;103:85–91.